The Weekly Term Sheet (2026-W11)
The second week of March 2026 represented a defining period for the global life sciences sector, as the industry transitioned from the volatility of previous fiscal cycles into a phase of disciplined but aggressive capital deployment. Between March 9 and March 13, 2026, the deal landscape was characterized by a surge in high-conviction "tuck-in" acquisitions, multi-billion dollar cross-border licensing agreements, and a concentration of venture capital into late-stage clinical assets.
This activity occurred against a backdrop of significant macro-economic tailwinds, including an estimated $2.1 trillion in available "firepower" among top-tier pharmaceutical companies. As major players approached a series of critical "patent cliffs"—particularly in the metabolic and cardiovascular spaces—the strategic imperative to replenish pipelines drove valuations to premium levels.
The market in early 2026 reflected a "Great Rebound," where the "biotech winter" valuations of the post-pandemic era were replaced by more robust, catalyst-driven pricing. This shift was catalyzed by a more predictable, albeit still rigorous, regulatory environment and a stabilization of interest rates that encouraged both public and private equity participation.
The week's transactions spanned the full spectrum of the healthcare ecosystem, from medical robotics and digital behavioral health platforms to neurovascular access technologies and next-generation epigenetic therapies.
The period was equally notable for clinical data events: AbbVie reported first obesity data for its amylin analog ABBV-295, BridgeBio presented expanded Phase 3 results for BBP-418 in limb-girdle muscular dystrophy, Ultragenyx reported positive Phase 3 gene therapy data in OTC deficiency, and UCB demonstrated head-to-head biologic superiority in psoriatic arthritis.
Strategic Mergers and Asset-Centric Acquisitions
In disclosed M&A, take-private, and tender activity, the week contained three large announced transactions (UHS/Talkspace, Agilent/Biocare, Medtronic/Scientia), one smaller public tender offer (Black Pearl/Selectis), and two micro-cap acquisitions (Aditxt/Ignite Proteomics, NeuroThera/CliniQuantum), totalling approximately $2.35 billion in announced consideration and enterprise value from the three principal deals, excluding undisclosed earn-outs and milestones in the Medtronic/Scientia deal.
The capital markets week was headlined by the EQT-led consortium's CHF 4.9 billion (~$6.3 billion) final exit from Galderma Group AG—the largest sponsor-backed block trade in history—alongside $450 million in convertible notes from Indivior, a $75 million ATM shelf from Prelude Therapeutics, and a $3 billion manufacturing commitment by Eli Lilly in China.
Agilent Technologies Acquisition of Biocare Medical
On March 9, 2026, Agilent Technologies announced a definitive agreement to acquire Biocare Medical, a leader in clinical and research pathology, for $950 million in an all-cash transaction from an investor group led by Excellere Partners and GHO Capital. This transaction represents a significant expansion of Agilent's pathology and cancer diagnostics portfolio, placing the newly acquired assets within Agilent's Life Sciences and Diagnostics Markets Group (LDG).
Technical Synergy and Market Positioning
Biocare Medical provides a highly complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions. These technologies are critical for high-precision oncology diagnostics, allowing clinicians to identify specific protein markers and genetic abnormalities in tissue samples.
IHC uses antibody-antigen interactions to detect proteins in tissue sections, ISH identifies specific DNA or RNA sequences within cells, and FISH employs fluorescent probes to map genetic material and detect chromosomal abnormalities—together forming the analytical backbone of modern precision oncology pathology. Biocare's specialized library of over 300 antibodies and its automated staining instrumentation are expected to bolster Agilent's ability to compete with dominant players like Roche and Danaher in the estimated $7+ billion global tissue diagnostics market.
The acquisition is strategically aligned with Agilent's recent moves, including the 2024 acquisition of BIOVECTRA, a contract development and manufacturing organization (CDMO), highlighting a broader strategy to move deeper into the clinical supply chain. Biocare generated more than $90 million in revenue in 2025, reflecting double-digit annual growth since 2021.
Financial Terms
The deal carries an implied multiple of approximately 10 times revenue, which analysts noted as a "demanding" but strategically justified price for Biocare's multiplexing technology and research capabilities. Agilent expects the transaction to be accretive to its top-line growth and margin profile within the first year, with earnings per share (EPS) accretion occurring approximately 12 months after the close. The deal is expected to close no later than Agilent's fourth fiscal quarter of 2026, subject to customary regulatory approvals.
Advisors
| Role | Agilent Technologies | Biocare Medical |
|---|---|---|
| Financial Advisor | Barclays | Jefferies (exclusive) |
| Legal Counsel | Sullivan & Cromwell LLP | Ropes & Gray LLP |
| Strategic Communications | Joele Frank | ICR Healthcare |
Universal Health Services Expansion via Talkspace Acquisition
In a landmark deal for the digital health sector, Universal Health Services (UHS) entered into a definitive agreement on March 9, 2026, to acquire Talkspace, Inc., for an enterprise value of approximately $835 million. UHS (NYSE: UHS), one of the largest operators of acute care and behavioral health facilities in the United States—operating 29 inpatient acute care facilities, 346 inpatient behavioral health facilities, and 168 outpatient and other facilities across the U.S., the U.K., and Puerto Rico—intends to leverage Talkspace's network of 6,000 licensed professionals to create the industry's first nationally scaled, end-to-end continuum in behavioral healthcare.
Strategic Rationale and Payor Mix Diversification
Talkspace (Nasdaq: TALK) provides virtual therapy and psychiatry sessions through a digital platform that matches patients with licensed therapists and psychiatrists for video, audio, chat, and asynchronous text messaging-based sessions. As of the end of 2025, its services were accessible to over 200 million individuals through insurance plans, employee assistance programs (EAPs), and employer/school/government agency benefits.
For UHS, the acquisition facilitates a seamless transition across care settings—from acute inpatient stays to intensive outpatient, partial hospitalization, and long-term virtual care—addressing a critical bottleneck where patients discharged from inpatient psychiatric care often face weeks-long waits to secure follow-up outpatient therapy within their insurance networks. The flow of patients is expected to be "bi-directional," as Talkspace providers will also refer members who need higher-acuity care to UHS physical facilities.
Furthermore, the move diversifies UHS's payor mix by increasing its exposure to commercially insured populations. Talkspace recorded revenue of $229 million in 2025, providing more than 1.6 million therapy sessions during that period.
Transaction Metrics and Timeline
- Price: $5.25 per share in cash (a 10.29% premium over the previous close)
- Board Approval: Unanimously approved by both UHS and Talkspace boards
- Financing: Borrowings from UHS's existing revolving credit facility
- EPS Impact: Excluding one-time costs, expected to be slightly accretive to UHS adjusted diluted EPS within the first 12 months post-closing and increasingly accretive thereafter
- Closing: Expected in the third quarter of 2026, subject to Talkspace shareholder and regulatory approvals
- Termination Fee: $32,394,000
Advisors
| Role | Universal Health Services | Talkspace, Inc. |
|---|---|---|
| Financial Advisor | J.P. Morgan Securities LLC | Wells Fargo Securities, LLC |
| Legal Counsel | McDermott Will & Schulte; Stevens & Lee | Cravath, Swaine & Moore LLP |
Medtronic Acquisition of Scientia Vascular
On March 10, 2026, Medtronic announced a definitive agreement to acquire Scientia Vascular, a private company specializing in neurovascular access products, for $550 million plus potential undisclosed earn-out and milestone payments. Based in Salt Lake City, Scientia Vascular's portfolio of guidewires and microcatheters is designed to navigate the brain's complex vasculature to treat acute ischemic and hemorrhagic strokes.
Innovation in Stroke Care
The acquisition strengthens Medtronic's Neuroscience Portfolio by integrating Scientia's proprietary microfabrication technology, which uses advanced microelectromechanical systems (MEMS) manufacturing techniques to produce guidewires and microcatheters with superior navigability and torque response. In neurointerventional procedures, where operators must navigate microcatheters through tortuous cerebral blood vessels as small as 1-2 mm in diameter, the quality of access devices directly impacts procedural success rates and patient outcomes.
Medtronic's leadership emphasized that "time is brain," and the integration of Scientia's access technology with Medtronic's therapeutic devices (including stent retrievers and aspiration catheters) creates a comprehensive workflow solution for stroke centers globally. This deal follows Medtronic's February announcement to acquire CathWorks for up to $585 million, signaling a sustained commitment to "tuck-in" acquisitions that bolster organic growth.
Financial and Operational Details
- Upfront Value: $550 million, subject to customary adjustments
- Contingent Consideration: Potential undisclosed earn-out and milestone payments post-acquisition
- Closing Timeline: Expected in the first half of Medtronic's fiscal year 2027, subject to regulatory approvals
- Financial Impact: Minimally dilutive to adjusted EPS in FY27 and accretive thereafter
Advisors
Advisors were not disclosed in Medtronic's announcement.
Black Pearl Equities Tender Offer for Selectis Health
On March 11, 2026, Black Pearl Equities, LLC commenced an all-cash tender offer to acquire up to 100% of outstanding shares of Selectis Health, Inc. (OTCQB: GBCS) at $5.05 per share. Selectis Health operates skilled nursing facilities and long-term care properties.
The offer terms are set out in a Schedule TO filed with the SEC and include a minimum tender condition. Abraham Schwartz (Brooklyn, NY) serves as Black Pearl's president. Separate reporting around the transaction references legal involvement by The Law Offices of Thomas C. Cook (Las Vegas), with D.F. King & Co. as information agent, Equiniti Trust Company as depositary, and Milrose Capital as funding source. Selectis Health has not yet filed its SC 14D-9 response.
Aditxt Acquisition of Ignite Proteomics
On March 11, 2026 (8-K earliest event date; press release dated March 13), Aditxt, Inc. (Nasdaq: ADTX) announced the acquisition of Ignite Proteomics, LLC, a commercial-stage precision oncology company previously operated as a subsidiary of IMAC Holdings, Inc. (OTCQB: BACK). The transaction was structured as a securities purchase agreement with IMAC Holdings and selling investors, with simultaneous note financing to support working capital and transaction-related needs.
Ignite Proteomics operates the only commercially available, clinically validated Reverse Phase Protein Array (RPPA) assay for cancer therapy selection. RPPA is a high-throughput, quantitative immunoassay technology that measures the expression and phosphorylation (activation) state of proteins directly from tumor biopsy material—a level of functional pathway analysis that standard genomic sequencing cannot provide.
While genomic testing identifies which mutations are present in a tumor, it cannot determine whether the corresponding protein signaling pathways are actually active and driving tumor growth. RPPA addresses this gap by simultaneously quantifying 32 phospho- and total-protein biomarkers across key oncogenic signaling cascades (including HER2, EGFR, AKT-mTOR, RET, TROP2, and MHC-II) from as little as a single core needle biopsy, enabling oncologists to match patients with targeted therapies most likely to be effective based on the actual molecular activity of their tumors rather than inferred genomic predictions.
Ignite's RPPA platform operates from a CLIA-certified, CAP-accredited, and New York State-approved laboratory. The clinical utility of the platform was validated by a landmark case study published in npj Precision Oncology demonstrating a complete response to HER2-directed therapy in a patient with HER2 IHC 0 breast cancer—a case where standard genomic testing would not have identified HER2 pathway activation. Ignite has established research collaborations with Vanderbilt University Medical Center (immuno-oncology biomarker discovery in breast cancer) and Inova Health (the first precision oncology trial to use functional proteomics for treatment decision-making in late-stage gastrointestinal cancers, with up to 600 tumor samples).
Ignite plans to launch a 2026 program supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options, targeting a $14 billion cancer profiling market and a $3 billion niche for targeted therapies and ADCs.
Transaction Structure and Concurrent Financing
| Component | Terms |
|---|---|
| Structure | Securities Purchase Agreement; 100% acquisition |
| Seller | IMAC Holdings, Inc. (OTCQB: BACK) and selling investors |
| Consideration | 36,000 shares of newly designated Series A-2 Convertible Preferred Stock ($36.0M aggregate stated value) |
| Preferred stock terms | Convertible into common stock at $2.731 per share (subject to adjustment); 9.99% beneficial ownership cap; company redemption rights |
| Cash component | Sellers delivered $475,000 in cash to Aditxt |
| Operating structure | Ignite will operate as a subsidiary within Aditxt's oncology initiatives |
Concurrent Note Financing:
| Component | Terms |
|---|---|
| Instrument | 10% original issue discount (OID) promissory notes |
| Aggregate principal | $3.194M |
| Gross proceeds | $2.875M |
| Interest rate | 6% (stepping to 12% upon event of default) |
| Maturity | 9 months from issuance |
| Purpose | Working capital and transaction-related needs |
Advisors
Advisors were not disclosed in the 8-K or press release.
Key Filing
NeuroThera Labs Acquisition of Majority Stake in CliniQuantum
On March 10, 2026, SciSparc Ltd. (Nasdaq: SPRC) announced that its majority-controlled subsidiary NeuroThera Labs Inc. (TSXV: NTLX) had entered into a definitive share purchase agreement to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQuantum Ltd. ("CliniQ"), an Israeli quantum technology company. SciSparc holds a controlling interest of approximately 75% in NeuroThera.
CliniQuantum holds patents from Ramot at Tel Aviv University in the fields of quantum simulation and quantum Monte Carlo methods. The company develops a next-generation platform that applies quantum computing to the analysis of complex clinical trial datasets, with the aim of designing faster, more adaptive clinical studies.
Quantum Monte Carlo methods use stochastic sampling algorithms—executed on quantum hardware or quantum-enhanced classical processors—to simulate probability distributions across high-dimensional parameter spaces, enabling the extraction of statistically meaningful patterns from clinical trial data that are computationally intractable for classical approaches.
For NeuroThera, a clinical-stage pharmaceutical company developing cannabinoid-based and combination therapeutics for central nervous system disorders (including SCI-110 for Tourette syndrome and Alzheimer's-related agitation, and SCI-210 for autism spectrum disorder and status epilepticus), the acquisition represents a platform-level strategic pivot—from developing individual drugs to owning enabling technology that could enhance clinical development across its entire portfolio and those of potential partners.
Transaction Structure and Earn-Out Terms
| Component | Terms |
|---|---|
| Structure | Definitive share purchase agreement (SPA dated March 9, 2026) |
| Target stake | 54.01% of CliniQuantum's issued and outstanding ordinary shares (56,375 CliniQ shares) |
| Consideration | 56,600,000 NeuroThera common shares (~$9.46M based on 20-day VWAP on TSXV) |
| Earn-out (aggregate cap) | Up to $2,500,000, payable in cash and/or NeuroThera shares at NeuroThera's sole discretion |
| Earn-out — patent milestones | $500,000 per patent application filed with USPTO or EPO, up to $1,500,000 aggregate (first three filings) |
| Earn-out — fundraising participation | 7.0% of NeuroThera fundraising proceeds, up to $1,000,000 aggregate |
| Earn-out period | Three years following closing |
| Expected closing | On or about March 31, 2026, within 30 days following submission of Israeli tax ruling application to the Israeli Tax Authority |
| Closing conditions | Satisfaction or waiver of customary conditions including Israeli tax ruling |
Advisors
Advisors were not disclosed in the announcement.
Licensing and Global Research Collaborations
The licensing market during the week was defined by complex, back-loaded milestone structures that allow larger pharmaceutical companies to access innovation while mitigating upfront capital risk. The highest-value disclosed structures were the GSK/Alfasigma linerixibat deal ($300M upfront + milestones) and the Rapport/Tenacia RAP-219 collaboration ($20M upfront + up to $308M milestones).
GSK and Alfasigma Licensing for Linerixibat
On March 9, 2026, GSK announced a global licensing agreement with Alfasigma, valued at up to $690 million, for the rights to linerixibat. Linerixibat is an investigational ileal bile acid transporter (IBAT) inhibitor designed to alleviate pruritus (chronic itching) in patients with primary biliary cholangitis (PBC).
The IBAT transporter mediates reabsorption of bile acids from the intestinal lumen; by inhibiting this transporter, linerixibat reduces circulating bile acid levels, which are believed to be a key driver of the debilitating itch experienced by PBC patients.
Financial Structure — Royalty and Milestone Breakdown
| Component | Amount | Trigger |
|---|---|---|
| Upfront payment | $300M | At signing |
| FDA approval milestone | $100M | Anticipated ahead of March 24, 2026 PDUFA date |
| EU & UK approval milestones | $20M | Upon respective regulatory approvals |
| Sales-based milestones | Up to $270M | Tiered commercial thresholds |
| Royalties | Tiered double-digit | On worldwide net sales (with reduction mechanisms for combination products, third-party license payments, generic competition, and COGS thresholds) |
Under the terms of the agreement, Alfasigma acquires exclusive worldwide rights to develop, manufacture, and commercialize linerixibat. GSK stated the deal allows the company to "sharpen its focus" on its next wave of liver disease innovation, including treatments for chronic hepatitis B and MASH (metabolic dysfunction-associated steatohepatitis). The transaction is subject to customary conditions including US HSR (Hart-Scott-Rodino) clearance.
Advisors
| Role | GSK | Alfasigma |
|---|---|---|
| Legal Counsel | Paul, Weiss, Rifkind, Wharton & Garrison LLP (Jonathan Ashtor, John Patten, Jeffrey Osterman, Brianna van Kan; antitrust: Christopher Wilson) | DLA Piper |
Rapport Therapeutics and Tenacia Biotechnology
On March 9, 2026, Rapport Therapeutics (Nasdaq: RAPP) and Shanghai-based Tenacia Biotechnology announced a strategic collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.
RAP-219 is a potential first-in-class TARPγ8-specific AMPA receptor negative allosteric modulator (NAM). TARPγ8 (transmembrane AMPA receptor regulatory protein gamma-8) is an auxiliary subunit of AMPA-type glutamate receptors that is enriched in the hippocampus and forebrain but has limited expression in the cerebellum and spinal cord.
By selectively targeting TARPγ8-containing AMPA receptors rather than all AMPA receptors globally, RAP-219 aims to suppress pathological neuronal hyperexcitability (the hallmark of epilepsy) while sparing AMPA receptor function in brain regions responsible for motor coordination and cognition—potentially offering a significantly improved side-effect profile over existing antiepileptic drugs. RAP-219 is being developed for focal onset seizures (FOS) and bipolar mania.
Financial Structure — Royalty and Milestone Breakdown
| Component | Amount | Trigger |
|---|---|---|
| Upfront cash payment | $20M | At signing |
| Development milestones | Up to ~$308M (aggregate) | Regulatory and commercial milestones |
| Royalties | Mid-single-digit to mid-teens (tiered) | On net sales in Greater China |
Tenacia's regional expertise is expected to accelerate the RAP-219 Phase 3 program by adding clinical trial sites in China, while Rapport retains all rights outside Greater China.
Advisors
| Role | Rapport Therapeutics | Tenacia Biotechnology |
|---|---|---|
| Financial Advisor | Goldman Sachs & Co. | — |
| Legal Counsel | Goodwin Procter LLP | Ropes & Gray LLP |
Hims & Hers and Novo Nordisk Collaboration
On March 9, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) filed an SEC exhibit (Ex. 99.1) announcing a US weight-loss distribution collaboration with Novo Nordisk A/S alongside a de-escalation of pending litigation. The deal represents a landmark shift in the branded-vs-compounded GLP-1 landscape.
GLP-1 (glucagon-like peptide-1) receptor agonists such as semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for obesity) mimic the incretin hormone GLP-1, which is secreted by intestinal L-cells in response to food intake. Semaglutide binds to GLP-1 receptors in the pancreas (stimulating glucose-dependent insulin secretion and suppressing glucagon), in the gastrointestinal tract (slowing gastric emptying), and in the hypothalamus (reducing appetite and food intake through central satiety signaling).
The 94% amino acid homology to native human GLP-1, combined with albumin binding and enzymatic resistance modifications that extend its half-life to approximately one week, has made semaglutide the dominant pharmacotherapy for obesity—with clinical trial weight reductions of 15–17% of body weight driving unprecedented demand that has strained global supply chains since 2023.
Under the terms:
- Novo Nordisk agreed to dismiss its lawsuit against Hims & Hers without prejudice
- Hims stated that Ozempic injections (0.5 mg, 1 mg, and 2 mg strengths) and Wegovy pills and injections (including multiple tablet strengths) are expected to become available on the Hims & Hers platform "later this month"
- Hims committed to stop advertising compounded GLP-1 offerings, and would offer compounded GLP-1s only where a provider determines clinical necessity for a limited set of customers
Financial terms were not disclosed in the SEC exhibit. The collaboration establishes a new paradigm in which branded pharmaceutical manufacturers partner directly with telehealth-driven direct-to-consumer platforms rather than competing against them in court.
Celularity and NEXGEL Commercialization Partnership
On March 10, 2026, Celularity Inc. (Nasdaq: CELU) announced a strategic commercialization partnership with NEXGEL, Inc. (Nasdaq: NXGL). Celularity, originally founded by Robert Hariri as a spin-off from Celgene focused on placenta-derived cell therapies and biomaterials, grants NEXGEL an exclusive licence to its commercial-stage biomaterials portfolio and certain development-stage programmes.
The placenta is a uniquely rich source of therapeutic biomaterials: its extracellular matrix contains high concentrations of collagen, hyaluronic acid, growth factors (including PDGF, TGF-β, and VEGF), and antimicrobial peptides that collectively promote wound healing, reduce inflammation, and support tissue regeneration.
Celularity's commercial biomaterials portfolio processes dehydrated human placental tissue into wound care membranes, surgical barriers, and tissue scaffolds used in chronic wound management, surgical repair, and regenerative medicine applications.
By licensing these marketed products to NEXGEL—which brings hydrogel formulation expertise and consumer health distribution channels—the partnership creates a combined platform spanning advanced wound care, topical drug delivery, and regenerative biomaterials.
Celularity retains exclusive manufacturing rights and will refocus resources on its longevity therapeutics pipeline, including its allogeneic placenta-derived natural killer (NK) cell therapies for cancer and its proprietary cryopreservation and cell banking technology.
| Component | Amount / Terms |
|---|---|
| Upfront cash payment | $15M |
| Development milestones | Up to $20M (tied to annual net sales targets) |
| Total non-dilutive consideration | Up to $35M |
| Royalties | On future net sales of certain development-stage products (rates undisclosed) |
| Manufacturing | Celularity retains exclusive manufacturing rights (Florham Park, NJ facility) |
| Revenue impact | NEXGEL expects deal to approximately triple annual revenue to ~$35M |
| Expected closing | No later than April 15, 2026 |
Advisors
| Role | Celularity | NEXGEL |
|---|---|---|
| Financial Advisor | pH Partners | — |
MiNK Therapeutics and C-Further Consortium
On March 10, 2026, MiNK Therapeutics (Nasdaq: MINK) announced its selection as a C-Further programme partner. C-Further is an international paediatric oncology therapeutics consortium enabled by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital (GOSH) Charity. The collaboration will advance a PRAME-targeted TCR-engineered iNKT (invariant natural killer T) cell therapy for paediatric cancers.
PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer-testis antigen overexpressed in a wide range of paediatric solid tumors while exhibiting minimal expression in normal tissues, making it an attractive target for engineered cell therapies. MiNK's platform engineers invariant natural killer T cells—a rare but potent subset of immune cells that combine properties of both innate and adaptive immunity—with T-cell receptors (TCRs) specific to PRAME, aiming to create an "off-the-shelf" allogeneic cell therapy that avoids the patient-specific manufacturing bottleneck of autologous CAR-T approaches.
MiNK will receive up to approximately $1.1 million in non-dilutive aggregate payments to advance IND-enabling work, with meaningful double-digit downstream commercial revenue participation potential. The agreement is non-exclusive, and MiNK retains full freedom to deploy its iNKT platform in other collaborations.
Enodia Therapeutics Acquisition of Kezar Assets
On March 12, 2026, Paris-based Enodia Therapeutics announced the acquisition of preclinical assets from Kezar Life Sciences' (Nasdaq: KZR) Sec61-based discovery and development program.
The Sec61 translocon is a protein-conducting channel embedded in the endoplasmic reticulum (ER) membrane responsible for translocating newly synthesized polypeptides into the ER lumen, where they are folded and processed for secretion or membrane insertion.
Enodia's platform exploits the Sec61 channel as a point of intervention: by selectively blocking the translocation of specific disease-driving proteins at the moment of synthesis, the approach achieves targeted protein degradation without requiring the ubiquitin-proteasome system that conventional degrader technologies (PROTACs, molecular glues) depend upon. This mechanism could address "undruggable" secreted and membrane-bound proteins that are inaccessible to existing degrader modalities.
Financial Structure — Royalty and Milestone Breakdown
| Component | Amount | Trigger |
|---|---|---|
| Upfront payment | $1M ($800K cash at closing; $200K upon inventory delivery within 45 days) | At signing |
| Development, regulatory, and commercial milestones | Up to $127M | Aggregate |
| Royalties | Single-digit tiered (with reductions for patent expiration, generic competition, and third-party license payments) | On net sales |
Enodia, launched in February 2025 by Argobio and the Institut Pasteur with a €20.7 million seed round co-led by Elaia, Pfizer Ventures, and Bpifrance, will integrate over a decade of Kezar's Sec61 research into its selective targeted protein degradation platform. Kezar retains its other pipeline programs, including zetomipzomib for autoimmune hepatitis.
Forge Genetics and AbbVie Licensing Agreement
On March 13, 2026, Nottingham-based Forge Genetics announced a licensing agreement with AbbVie granting an exclusive licence to use its proprietary "Forge Editing" genome editing platform within a limited field. The agreement includes an upfront payment and development milestone payments; financial terms were not disclosed.
Forge Genetics' platform is designed for engineering difficult-to-modify organisms and has demonstrated results in cases where other gene-editing approaches—including Cas9-based systems—have struggled, with applications spanning non-model microbial engineering and mammalian cell modification. The deal represents an early-stage platform validation for a UK deep-tech biotech by a top-five global pharmaceutical company.
Venture Capital and Early-Stage Financing Rounds
The venture capital (VC) landscape for the week showed a concentration of funding into larger rounds for later-stage startups, particularly those focused on neuropsychiatry, immunology, and digital health. Investors have prioritized "de-risked" opportunities with strong proof-of-concept data.
Significant Venture and Growth Funding Rounds (March 9–13, 2026)
| Company | Deal Date | Amount | Funding Type | Focus / Technology | Key Investors |
|---|---|---|---|---|---|
| Alan | March 11, 2026 | €100M | Growth | Digital health insurance platform (€785M ARR) | Index Ventures, Belfius |
| Vima Therapeutics | March 11, 2026 | $100M | Series A Extension | VIM0423 for dystonia and Parkinson's (M1/M4 muscarinic) | Atlas Venture |
| Vitestro | March 10, 2026 | $70M | Series B (oversubscribed) | Autonomous robotic phlebotomy | Labcorp, Mayo Clinic, Sutter Health |
| Translucent | March 11, 2026 | $27M | Series A | AI platform for healthcare revenue cycle finance | GV (Google Ventures), NEA |
| Sandbar | March 10, 2026 | $23M | Series A | Wearable conversational AI interface | Adjacent, Kindred Ventures |
| Unreasonable Labs | March 10, 2026 | $13.5M | Seed | AI-native knowledge discovery engine | Playground Global |
| VALANX Biotech | March 12, 2026 | €3M | Series A | ADC targeting LIV-1 for mTNBC (GoldenSite platform) | Foundation Fournier-Majoie, FUJIFILM, xista science ventures, tecnet equity, SOSV |
Notable Venture Themes
Neuroscience and movement disorders: Vima Therapeutics, founded and incubated at Atlas Venture, is advancing VIM0423, a potential first-in-class oral treatment that targets muscarinic cholinergic receptors (specifically M1 and M4 subtypes) to treat isolated dystonia and Parkinson's disease. The muscarinic approach aims to restore the balance between cholinergic and dopaminergic signaling in the basal ganglia, a circuit disruption central to movement disorders. Vima disclosed the dosing of its first dystonia patient in a Phase 2 study concurrent with the Series A extension announcement.
Autonomous medical robotics: Vitestro's $70M oversubscribed round, backed by strategic investors Labcorp, Mayo Clinic, and Sutter Health, funds commercialization of its autonomous robotic phlebotomy system—a device that uses computer vision and robotic needle guidance to perform venipuncture without a human operator. The technology addresses a critical labor shortage in phlebotomy, with an estimated 25% vacancy rate in US clinical laboratory staffing as of 2025.
ADC linker innovation: Vienna-based VALANX Biotech raised €3 million to advance VLX-ADC-001, an antibody-drug conjugate targeting LIV-1 (also known as ZIP6/SLC39A6, a zinc transporter overexpressed in multiple cancers) for metastatic triple-negative breast cancer (mTNBC).
VALANX's proprietary GoldenSite conjugation platform enables site-specific, reproducible attachment of cytotoxic payloads to antibodies at precisely defined positions, addressing a fundamental challenge in ADC manufacturing: controlling the drug-to-antibody ratio (DAR) and ensuring batch-to-batch consistency. The company, a spin-off from the Paul Scherrer Institute (ETH domain), plans candidate selection by June 2026. Investors include Foundation Fournier-Majoie, FUJIFILM Corporation, xista science ventures, tecnet equity, SOSV, and angel investors Urs Spitz and SkyGene. Ana Maricevic joined the VALANX Board of Directors representing Foundation Fournier-Majoie.
AI-Native Discovery and Platform Partnerships
The week of March 9 continued the integration of artificial intelligence as a central component of drug development partnerships.
Breakout Ventures AI-Focused Life Sciences Fund
On March 10, 2026, Breakout Ventures launched a $114 million fund dedicated to AI-driven life sciences investments. The fund targets early-stage companies that apply artificial intelligence and machine learning to drug discovery, diagnostics, and biological data analysis. The launch reinforces the broader trend of dedicated AI-bio investment vehicles emerging as the sector moves from treating AI as a "discovery tool" toward using it as a core "operating system" for R&D.
Notable Clinical Data Readouts
The week of March 9–13 produced several significant clinical data events that have direct implications for pipeline valuations, competitive positioning, and future dealmaking across therapeutic areas.
AbbVie ABBV-295 Phase 1 Obesity Data
On March 9, 2026, AbbVie announced positive topline results from the multiple ascending dose (MAD) portion of its Phase 1 study of ABBV-295, a long-acting amylin analog being developed for obesity. ABBV-295 is an agonist that activates both amylin and calcitonin receptors, representing a mechanistically distinct class from the incretin-based GLP-1 and GIP receptor agonists (semaglutide, tirzepatide) that currently dominate the obesity treatment landscape.
Amylin is a satiety hormone co-secreted with insulin from pancreatic beta cells that suppresses appetite, reduces food intake, and delays gastric emptying through central signaling via the area postrema and nucleus of the solitary tract—a pathway independent of GLP-1 signaling. The first-generation amylin analog pramlintide (Symlin) was approved for diabetes but required thrice-daily dosing due to aggregation challenges; ABBV-295's long-acting formulation overcomes this limitation, enabling weekly to monthly subcutaneous administration.
In the MAD study (76 participants, 88.3% male, mean BMI <30), ABBV-295 produced dose-dependent least-squares mean body weight reductions of −7.75% to −9.79% at week 12 (weekly dosing) and −7.86% to −9.73% at week 13 (every-other-week and monthly dosing after week 5), compared to −0.26% and −0.25% for placebo. The drug was generally well tolerated across all dose levels, with no serious adverse events and mostly mild gastrointestinal side effects concentrated in the first six weeks.
The data position AbbVie as a credible late entrant in the obesity space, with analysts at BMO and RBC noting the results support continued Phase 2 development, albeit with a projected 2030 market entry timeframe. Key amylin-class competitors include Novo Nordisk's cagrilintide (in Phase 3 REDEFINE trials with semaglutide), Zealand Pharma/Roche's petrelintide (Phase 2), Eli Lilly's eloralintide (which demonstrated 20% weight loss in a mid-stage study in November 2025), and Novo Nordisk's amycretin (dual GLP-1/amylin agonist approaching Phase 3).
BridgeBio Pharma Phase 3 FORTIFY Data (BBP-418 / Ribitol in LGMD2I/R9)
On March 11, 2026, BridgeBio Pharma presented expanded positive interim data from the Phase 3 FORTIFY trial of oral BBP-418 (ribitol) in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), in a late-breaking oral presentation at the MDA Clinical and Scientific Conference in Orlando.
LGMD2I/R9 is a monogenic autosomal recessive disease caused by biallelic mutations in the fukutin-related protein (FKRP) gene, which encodes a glycosyltransferase responsible for adding ribitol-5-phosphate to the sugar chain on alpha-dystroglycan (αDG). Hypoglycosylation of αDG disrupts the structural link between the muscle cell membrane and the extracellular matrix, leading to progressive proximal muscle degeneration, loss of ambulation, cardiomyopathy, and respiratory failure.
Most FKRP mutations are hypomorphic, meaning residual enzymatic activity persists—a critical insight that underpins BBP-418's mechanism: exogenous ribitol supplementation provides substrate to drive the impaired but still partially functional FKRP enzyme to increase glycosylation of αDG and restore the dystroglycan-matrix connection.
FORTIFY interim data showed separation from placebo on the 100-meter timed test as early as three months, with BBP-418-treated participants completing the test approximately 31 seconds faster than placebo at 12 months.
Serum creatine kinase, a biomarker of ongoing muscle damage, showed rapid and sustained reductions, with 59.6% of participants achieving levels within twice the upper limit of normal at 12 months. At week 24, 71% of treated patients rated themselves as "much improved" on the patient global impression of change scale for overall symptoms, compared with 0% on placebo.
Safety was favorable, with adverse event rates comparable between arms and no treatment-related serious adverse events. No FDA-approved therapies currently exist for LGMD2I/R9 or any LGMD subtype, and BridgeBio intends to submit an NDA for traditional approval in the first half of 2026, with a US launch anticipated in late 2026 or early 2027. BBP-418 has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA.
Ultragenyx DTX301 Phase 3 Data in OTC Deficiency
On March 12, 2026, Ultragenyx Pharmaceutical announced positive 36-week results from the Phase 3 Enh3ance study of DTX301 (avalotcagene ontaparvovec), an investigational AAV8 gene therapy for ornithine transcarbamylase (OTC) deficiency—the most common urea cycle disorder, affecting an estimated 10,000 people worldwide.
OTC deficiency is caused by genetic defects in the mitochondrial enzyme ornithine transcarbamylase, which catalyzes the condensation of ornithine and carbamoyl phosphate to form citrulline in the urea cycle—the liver's primary pathway for converting toxic ammonia into urea for excretion.
Patients face lifelong dependence on ammonia scavenger medications (sodium benzoate, glycerol phenylbutyrate) and severely protein-restricted diets, with persistent risk of unpredictable hyperammonemic crises that can cause acute neurological damage or death; liver transplantation remains the only curative approach.
DTX301 delivers a functional copy of the OTC gene via a single intravenous infusion of an AAV8 vector that preferentially transduces hepatocytes. In the randomized, double-blind, placebo-controlled Enh3ance trial (n=37 across 16 sites in 10 countries), DTX301-treated patients (n=18) demonstrated a statistically significant 18% reduction in 24-hour plasma ammonia (AUC₀₋₂₄) versus placebo (n=19; p=0.018) at week 36, maintaining average ammonia within the normal range. Eight of nine patients with abnormal baseline ammonia levels normalized rapidly despite a 27% mean decrease in scavenger medication use and ~13% increase in protein intake.
Safety was acceptable, with transient hepatic reactions manageable with steroids; notably, hyperammonemic crises requiring hospitalization occurred five times in the placebo group (including one death) versus once in the DTX301 arm (no deaths). The study continues to a second co-primary endpoint evaluating treatment burden reduction through 64 weeks, with data expected in the first half of 2027. DTX301 holds Orphan Drug and Fast Track designations in the US and EU.
UCB Bimekizumab BE BOLD Superiority Data in Psoriatic Arthritis
On March 11, 2026, UCB announced positive topline data from the BE BOLD trial, a Phase 3b head-to-head study comparing bimekizumab (Bimzelx) with risankizumab (Skyrizi, AbbVie/Boehringer Ingelheim) in adults with active psoriatic arthritis.
Bimekizumab, a humanized IgG1 monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), achieved statistically significant superiority over risankizumab on the primary ACR50 endpoint at week 16 in the multicenter, randomized, double-blind study of 553 adults. IL-17A and IL-17F drive inflammation in psoriatic arthritis through overlapping but non-redundant pathways, promoting synovial hyperplasia and joint destruction; preclinical evidence suggests dual IL-17A/F inhibition reduces synovial tissue inflammation beyond IL-17A blockade alone.
Risankizumab targets the p19 subunit of IL-23, acting upstream in the Th17 axis. The BE BOLD result suggests that direct cytokine neutralization at the IL-17 effector level may yield greater joint-level efficacy than upstream IL-23 blockade at 16 weeks, and makes bimekizumab the first licensed biologic to demonstrate superiority over an IL-23 inhibitor in psoriatic arthritis—the fourth head-to-head superiority result in the bimekizumab clinical program (following wins versus secukinumab, ustekinumab, and adalimumab in plaque psoriasis).
Key competitors in the PsA landscape include Novartis's Cosentyx (secukinumab), Eli Lilly's Taltz (ixekizumab), Janssen's Tremfya (guselkumab), and Bristol Myers Squibb's Sotyktu (deucravacitinib), which received FDA approval for active psoriatic arthritis on March 6, 2026.
Initial Public Offerings (IPOs) and Capital Market Activity
The first quarter of 2026 saw a robust reopening of the life sciences IPO market, supported by strong performance in biotech indices. The week of March 9–13 was unusually heavy for biotech capital markets activity, with two massive follow-on offerings (Dianthus at $719M and Xenon at $747.5M) both pricing at significant upsizes and seeing full exercise of underwriter options, two upsized convertible note offerings (CRISPR at $550M and Indivior at $450M), a $160M oversubscribed PIPE (Relmada), and the EQT-led consortium's CHF 4.9 billion (~$6.3 billion) final exit from Galderma—the largest sponsor-backed block trade in history—demonstrating exceptional institutional appetite across the capital structure.
MiniMed Group IPO Closing
On March 9, 2026, MiniMed Group, Inc., a subsidiary of Medtronic, officially closed its IPO, having priced 28,000,000 shares at $20.00 each. The transaction raised approximately $560 million in gross proceeds. MiniMed, a global leader in insulin delivery systems including insulin pumps, continuous glucose monitoring (CGM) integration, and automated insulin delivery (AID) algorithms, began trading on the Nasdaq under the symbol "MMED." Post-IPO, Medtronic remains the majority stakeholder, holding roughly 90% of the company.
MiniMed's AID systems represent the leading edge of diabetes technology: closed-loop algorithms continuously read interstitial glucose levels from a CGM sensor, predict glucose trajectories using mathematical models, and automatically modulate basal insulin delivery from a body-worn pump—adjusting rates every five minutes to maintain glucose in a target range without manual user intervention. This "artificial pancreas" approach has been shown to improve time-in-range (70–180 mg/dL) by 10–15 percentage points versus sensor-augmented pump therapy, reducing both hypoglycemia and hyperglycemia events.
The carve-out and separate listing allows MiniMed to pursue a more focused innovation strategy in the rapidly evolving diabetes technology market, where competition from Insulet (Omnipod), Tandem Diabetes Care, and vertically integrated CGM/pump platforms is intensifying.
IPO Bookrunners and Advisors
| Role | Firm |
|---|---|
| Active Bookrunners | Goldman Sachs, BofA Securities, Citigroup, Morgan Stanley |
| Joint Bookrunners | Barclays, Deutsche Bank, Mizuho, Wells Fargo, Evercore ISI, Piper Sandler |
| Co-Managers | BTIG, William Blair |
| Issuer Counsel | Cleary Gottlieb Steen & Hamilton LLP (Adam Fleisher, Kimberly Spoerri, Synne Chapman); Latham & Watkins LLP (separation and credit facility) |
| Medtronic Separation Counsel | Baker McKenzie (global counsel to Medtronic on the MiniMed carve-out and spin-off) |
| Underwriter Counsel | Davis Polk & Wardwell LLP (John Meade, Yasin Keshvargar, Arisa Sin) |
Public Market Transactions (March 9–13, 2026)
Dianthus Therapeutics — Underwritten Follow-on ($719M)
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotechnology company developing next-generation complement therapeutics for severe autoimmune diseases, launched a $400M underwritten public offering on March 9 that was subsequently upsized to $625M at pricing ($81.00/share) on March 10, and closed at $719M on March 12–13 after the underwriters exercised their 30-day option in full for an additional 1,157,407 shares.
Net proceeds were approximately $673.5M after underwriting discounts. Proceeds will fund clinical and preclinical development activities and commercial readiness.
The offering coincided with Dianthus's announcement of an early GO decision in the Phase 3 CAPTIVATE trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP) on March 9—the catalyst that drove both the stock surge and the upsize.
Claseprubart is a monoclonal antibody engineered to selectively target only the active form of C1s, the serine protease that initiates the classical complement pathway. When autoantibodies bind to self-antigens and recruit the C1 complex (C1q, C1r, C1s), activated C1s cleaves C4 and C2, triggering a proteolytic cascade that generates the membrane attack complex and pro-inflammatory split products C3a and C3b.
By intercepting this cascade at C1s—the most upstream enzymatic step—claseprubart inhibits classical pathway-mediated tissue damage while leaving the lectin and alternative complement pathways intact, potentially avoiding the increased risk of meningococcal and encapsulated bacterial infections associated with downstream C5 inhibitors (eculizumab, ravulizumab) that carry FDA Boxed Warnings and mandatory REMS programs.
Claseprubart is further differentiated by its selectivity for the active conformer of C1s: because active C1s constitutes only a small fraction of total circulating C1s protein, targeting it specifically allows therapeutic efficacy at lower doses and less frequent administration (subcutaneous Q2W via an autoinjector) compared to sutimlimab (Sanofi's marketed C1s inhibitor, which binds both active and inactive forms and requires intravenous infusion).
Phase 2 MaGic trial data in generalized myasthenia gravis (gMG) showed robust efficacy, and Phase 3 trials are planned in gMG (mid-2026 start) and multifocal motor neuropathy (MMN, top-line data expected 2H 2026). The company ended 2025 with approximately $514M in cash, and the $673.5M in net offering proceeds extends its runway into 2028, covering all major Phase 3 readouts.
| Role | Firm(s) |
|---|---|
| Joint Book-Running Managers | Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities, William Blair |
| Financial Advisor | LifeSci Capital |
| Issuer Counsel | Gibson, Dunn & Crutcher LLP (Ryan Murr, Branden Berns, Melanie Neary) |
Xenon Pharmaceuticals — Underwritten Follow-on ($747.5M)
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company developing ion channel therapies, launched a $500M underwritten offering on March 9, upsized to $650M at pricing ($57.00/share) on March 10, and closed at $747.5M on March 12–13 including full exercise of the underwriters' option for 1,710,526 additional shares. Net proceeds were approximately $707.7M after underwriting discounts.
The offering was catalyzed by the release of Phase 3 X-TOLE2 data for azetukalner (formerly XEN1101) in focal-onset seizures on March 9, with results that analysts characterized as best-in-class. Azetukalner is a potent, selective opener of Kv7.2/7.3 (KCNQ2/3) voltage-gated potassium channels—the molecular basis of the neuronal M-current, a tonic hyperpolarizing current that stabilizes resting membrane potential and limits repetitive neuronal firing.
For a neuron to generate an action potential, sodium channels open to depolarize the membrane; potassium channels then open to repolarize and return the neuron to its resting state. By pharmacologically holding Kv7.2/7.3 channels open longer, azetukalner keeps neurons in a more hyperpolarized state, raising the threshold for pathological repetitive firing that characterizes seizure activity.
This mechanism is fundamentally distinct from the sodium channel blockade, GABAergic modulation, or SV2A targeting employed by the majority of existing antiseizure medications, making azetukalner the first Kv7 opener in Phase 3 development since the withdrawal of ezogabine (retigabine) in 2017 due to retinal and skin pigmentation changes.
Azetukalner's tertiary aniline structure prevents the formation of the chromophoric dimers responsible for ezogabine's pigmentation liability, and no pigmentation-related adverse effects have been observed in clinical studies to date. Azetukalner requires no dose titration—reaching effective plasma levels on Day 1—a significant clinical advantage over competitors such as cenobamate (Xcopri), which requires a 12-week titration period.
Xenon is also advancing azetukalner in Phase 3 for major depressive disorder (MDD) and bipolar depression (BPD), based on the rationale that Kv7 channel modulation regulates excitability in mood-related neural circuits; Phase 2 X-NOVA data showed significant improvement in anhedonia, a core symptom of MDD poorly addressed by existing SSRIs. Long-term open-label extension data from X-TOLE showed median monthly seizure frequency reductions reaching 90.9% by month 48.
| Role | Firm(s) |
|---|---|
| Joint Book-Running Managers | J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, William Blair |
| Lead Manager | Baird |
CRISPR Therapeutics — Convertible Senior Notes ($550M)
CRISPR Therapeutics (Nasdaq: CRSP), headquartered in Zug, Switzerland, announced on March 10 its intention to offer $350M of convertible senior notes due 2031. Strong demand allowed the company to upsize to $550M in aggregate principal at pricing on March 11.
The notes carry a 2031 maturity, with semiannual interest (March 1 and September 1), an initial conversion rate of 13.0617 shares per $1,000 principal (equivalent to an initial conversion price of approximately $76.56, a 45% premium to the March 10 closing price of $52.80). The underwriters were granted an option to purchase up to an additional $50M in notes. Closing expected March 16. Rule 144A private placement to qualified institutional buyers.
Proceeds are earmarked for general corporate purposes to support CRISPR's expanding gene-editing franchise, anchored by Casgevy (exagamglogene autotemcel), the world's first approved CRISPR/Cas9-based gene therapy, developed in collaboration with Vertex Pharmaceuticals.
Casgevy received FDA and EMA approval in late 2023 for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD), and represents a one-time functional cure: patient hematopoietic stem cells are harvested, edited ex vivo using CRISPR/Cas9 to reactivate fetal hemoglobin (HbF) production by disrupting the BCL11A erythroid enhancer, and reinfused following myeloablative conditioning. Reactivated HbF compensates for the defective adult hemoglobin that drives both TDT and SCD pathology.
Beyond Casgevy, CRISPR is advancing a pipeline of next-generation allogeneic cell therapies using gene-edited donor-derived T cells: CTX112 (anti-CD19 CAR-T for B-cell malignancies), CTX131 (anti-CD70 for renal cell carcinoma and other solid tumors), and CTX310/CTX320 (in vivo gene-editing programs targeting ANGPTL3 and PCSK9, respectively, for cardiovascular disease).
The in vivo programs use lipid nanoparticle-delivered CRISPR to edit genes directly in the liver without ex vivo cell manipulation—a modality shift that could dramatically expand the addressable patient population beyond the autologous manufacturing bottleneck.
The $550M convertible offering, issued at a time when CRSP shares had declined significantly from 2021 peaks, reflects institutional confidence in the long-term platform value of CRISPR's gene-editing technology across both rare disease and large-market indications.
Issuer counsel: Goodwin Procter LLP (Jim Barri, Kim De Glossop, Robert Puopolo). Initial purchaser names are expected to appear in the indenture/purchase agreement filed upon closing.
Relmada Therapeutics — PIPE ($160M)
Relmada Therapeutics (Nasdaq: RLMD) announced an oversubscribed $160M private investment in public equity (PIPE) on March 9. The company sold 29,474,569 common shares at $4.75 and pre-funded warrants for 4,210,527 shares at $4.749 (exercise price $0.001). Expected closing approximately March 11, 2026. Proceeds will fund the Phase 3 Reliance registration program for REL-1017 (esmethadone), a novel uncompetitive NMDA receptor channel blocker being developed as an adjunctive treatment for major depressive disorder (MDD).
Esmethadone is the dextro-isomer (d-isomer) of racemic methadone—structurally related but pharmacologically distinct: while levomethadone (the l-isomer) is the opioid-active component, esmethadone is devoid of meaningful opioid agonist effects and has been confirmed by the DEA to lack significant abuse liability and respiratory depressant activity.
Esmethadone works by preferentially blocking pathologically hyperactive NMDA receptor channels of the GluN1-GluN2D subtype. In MDD, excessive tonic calcium influx through hyperactive GluN2D-containing NMDA receptors is hypothesized to dysregulate the eEF2 kinase/BDNF signaling axis, reducing the homeostatic availability of synaptic proteins required for neural plasticity.
By selectively blocking these hyperactive channels—without interfering with physiological NMDA receptor activity in other subtypes—esmethadone restores BDNF-mediated and mTORC1-dependent synaptic protein synthesis, producing rapid antidepressant effects mechanistically similar to ketamine but without the dissociative, psychotomimetic, or addictive properties.
Phase 2 data demonstrated rapid, robust, and sustained antidepressant effects at 25 mg and 50 mg daily doses in patients with inadequate response to one to three prior antidepressant courses, with efficacy onset at Week 1 and sustained improvement for one week after treatment discontinuation.
The oversubscribed PIPE—attracting a roster of prominent healthcare investors including Venrock, RA Capital, OrbiMed, Janus Henderson, and Commodore Capital—reflects institutional conviction in the NMDA mechanism for depression following the commercial success of esketamine (Spravato) and dextromethorphan-bupropion (Auvelity), and positions esmethadone as a potential best-in-class adjunctive MDD treatment with a differentiated safety profile.
| Role | Firm(s) |
|---|---|
| Placement Agents | Jefferies, Leerink Partners, Piper Sandler, Mizuho |
| Named Investors | Venrock Healthcare Capital Partners, Commodore Capital, Janus Henderson, RA Capital, Balyasny, OrbiMed, Spruce Street, Squadron, Columbia Threadneedle, Adage, Marshall Wace, Braidwell, Great Point Partners, Eventide (among others) |
EQT-Led Consortium Final Exit from Galderma Group AG (CHF 4.9 Billion Block Trade)
In the largest sponsor-backed block trade in history, EQT AB, the Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte (GIC) completed the sale of their remaining 14.3% stake in Galderma Group AG (SIX: GALD) through an accelerated bookbuild priced on March 10 and completed on March 13, 2026. The placement comprised approximately 34 million shares at CHF 143.75 per share, generating aggregate gross proceeds of approximately CHF 4.9 billion (~$6.3 billion).
Galderma repurchased 1.6 million shares as part of the transaction. The deal was increased twice during execution on the back of strong investor demand and was reported to be multiple times oversubscribed at the final price.
The exit concludes an investment cycle that began when the EQT-led consortium carved Galderma out of Nestlé in October 2019 for CHF 10.2 billion (including debt). Under EQT's ownership, Galderma delivered double-digit revenue growth from $2.8 billion (2018) to $5.2 billion (2025), with organic revenue growth accelerating from mid-single digits at entry to approximately 18% in 2025, and more than doubled EBITDA from $520 million to $1.2 billion over the same period.
Galderma went public on the SIX Swiss Exchange in March 2024 in one of Europe's largest IPOs that year (CHF 2.3 billion), and its share price nearly tripled from the IPO price of CHF 53 to the block trade level. Since the IPO, the consortium monetized approximately 77% of the company's share capital through seven accelerated bookbuilds and two private stake sales (including a 20% stake to L'Oréal Groupe in two tranches), realizing total aggregate proceeds of approximately CHF 21 billion (~$26 billion)—the largest value-creation outcome in EQT's history and a more than fourfold return on invested capital.
The transaction is notable not only for its scale but for its execution timing amid elevated equity market volatility following sharp US market declines earlier in the week.
| Role | Firm(s) |
|---|---|
| Joint Global Coordinators and Bookrunners | Goldman Sachs International, Morgan Stanley, UBS, Citigroup Global Markets, Jefferies, J.P. Morgan Securities |
Other Capital Market Transactions
| Company | Transaction Type | Amount | Date | Agents / Advisors | Note |
|---|---|---|---|---|---|
| Galderma Group AG | Eurobond Issuance | €500M | March 10, 2026 | Citigroup, ING, J.P. Morgan, RBC Capital Markets (joint leads); Advestra AG (issuer counsel; Annette Weber); Baker McKenzie (banking syndicate counsel) | 3.375% coupon; 5-year maturity; listed on SIX Swiss Exchange; rated BBB by Fitch (stable) and S&P (positive); refinancing IPO-related bank term loan; settlement March 17. Issued concurrently with the EQT-led consortium's CHF 4.9B final exit block trade (see above) |
| BioXcel Therapeutics | Registered Direct | ~$8M | March 10, 2026 | Rodman & Renshaw LLC (exclusive placement agent) | Shares, common stock equivalents, and accompanying warrants to an institutional investor; closed March 11 |
| Prelude Therapeutics | ATM Offering | Up to $75M | March 12, 2026 | Jefferies LLC (sales agent) | Prospectus supplement filed under existing Open Market Sale Agreement |
Indivior PLC — Convertible Senior Notes ($450M)
Indivior PLC priced $450M in convertible senior notes on March 12–13, 2026, upsized from an initial $400M offering. The notes carry a 0.625% coupon, March 2031 maturity, and an initial conversion price of approximately $41.66 (a 35% premium to the reference price), with a $50M greenshoe option. Proceeds are allocated to approximately $239M plus $102M in cash to repay and terminate existing credit facilities, and approximately $75M for concurrent share repurchases.
Settlement is expected March 17. Rule 144A private placement to qualified institutional buyers; initial purchaser names were not publicly disclosed.
Indivior is a global specialty pharmaceutical company focused on developing medicines for substance use disorders and serious mental illnesses. Its commercial franchise is anchored by SUBLOCADE (buprenorphine extended-release injection), a monthly subcutaneous depot formulation that delivers sustained therapeutic buprenorphine levels for opioid use disorder (OUD) without requiring daily dosing compliance—addressing the central challenge of OUD treatment adherence.
Buprenorphine is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist that occupies opioid receptors sufficiently to suppress withdrawal symptoms and cravings while producing a "ceiling effect" on respiratory depression, conferring a significantly improved safety profile over full agonists such as methadone. SUBLOCADE's ATRIGEL delivery system forms a solid depot upon subcutaneous injection, releasing buprenorphine continuously over 28 days.
The pipeline includes OPVEE (nalmefene nasal spray, an opioid antagonist for emergency reversal of opioid overdose) and PERSERIS (risperidone extended-release injection for schizophrenia). The upsized offering reflects institutional demand for Indivior's defensive positioning in the growing opioid treatment market.
Salspera — IPO Filing (~$85M)
Salspera filed its S-1/A on March 10, 2026, targeting approximately $85M in gross proceeds for a Nasdaq listing under ticker "TKVA." Kingswood Capital Partners is sole book-running manager; Ellenoff Grossman & Schole LLP serves as issuer counsel and Greenberg Traurig LLP as underwriter counsel. The company holds FDA Fast Track and Orphan Drug designations for its lead asset.
Salspera's Saltikva (Salmonella-IL2) is a first-in-class live biopharmaceutical: an attenuated strain of Salmonella typhimurium genetically engineered to carry the human interleukin-2 (IL-2) gene. The strain is rendered avirulent through deletion of the cya and crp virulence genes and lacks the enzyme aspartate semialdehyde dehydrogenase, creating a biological containment mechanism whereby the bacterium cannot survive without its engineered plasmid—preventing reversion to wild-type pathogenicity.
When orally administered, Saltikva exploits Salmonella's natural ability to invade intestinal mucosa and preferentially colonize solid tumor tissue at a ratio of 1,000–10,000:1 over normal liver tissue. Once established within the tumor microenvironment, the bacteria locally secrete IL-2, a cytokine that expands populations of natural killer (NK) cells and CD8+ cytotoxic T cells, provoking an immunologically mediated cancer cell kill in situ without the systemic toxicity that has historically limited intravenous IL-2 therapy.
In a Phase 2 trial, patients with stage IV metastatic pancreatic ductal adenocarcinoma who received more than five doses of Saltikva with FOLFIRINOX chemotherapy achieved a median overall survival of 20.3 months and a 70% overall response rate—nearly double the approximately 11.1-month median survival observed historically with FOLFIRINOX alone. No serious adverse events were attributed to Saltikva.
The approach addresses one of oncology's most intractable challenges: pancreatic cancer's immunologically "cold" tumor microenvironment, which has rendered checkpoint inhibitors largely ineffective in this indication.
Growth Capital
Monteris Medical (private; Minnetonka, MN), the developer and marketer of the NeuroBlate System—a robotically controlled laser interstitial thermal therapy (LITT) platform that uses MRI-guided laser technology to precisely destroy abnormal brain tissue including brain tumors, radiation necrosis, and drug-resistant epilepsy—announced a combined $63 million financing package on March 12, 2026.
LITT works by inserting a thin laser fiber through a small burr hole in the skull, guided by real-time MRI thermometry that maps tissue temperature in three dimensions during ablation.
The MRI feedback loop allows the neurosurgeon to monitor the thermal damage zone in real time, ensuring complete ablation of the target lesion while preserving surrounding eloquent brain tissue—a precision advantage over conventional open craniotomy that translates to shorter hospital stays (typically 1–2 days vs. 5–7 days for open surgery), reduced infection risk, and faster recovery.
NeuroBlate's robotic interface—the only LITT system with robotic probe control—enables sub-millimeter positioning accuracy and automated trajectory execution, reducing operator variability. The system is deployed across nearly 130 health systems in North America, and the company has treated patients with glioblastoma, metastatic brain tumors, meningiomas, and mesial temporal sclerosis-related epilepsy.
| Transaction | Amount | Counterparties | Details |
|---|---|---|---|
| Series E Equity | $28M | Lead: InnovaHealth Partners, Birchview Capital; New: OSF Ventures, Colorado University Healthcare Innovation Fund | Proceeds for U.S. commercial expansion, technology innovation, clinical research, and geographic expansion |
| Growth Credit Facility | $35M | Trinity Capital (Nasdaq: TRIN) | Refinancing and retirement of prior Madryn Asset Management facility; longer-term, lower-cost debt; near-term pathway to profitability cited |
Mayank Taneja (VP, Venture Investments, OSF Ventures) and Alex Marcantonio (Managing Director, Madryn Asset Management) joined the Monteris board of directors.
Financial Distress, Restructuring, and Bankruptcies
Despite the prevailing "firepower" in the sector, the week of March 9, 2026, served as a reminder of the "perilous fundraising situation" for companies without differentiated assets or near-term catalysts. Bankruptcies in the biopharma space remain at a 10-year high, with 13 firms failing in 2024 and activity continuing into 2026.
Distressed Asset Sales and Auctions
Omega Therapeutics: A Flagship Pioneering spinout focused on epigenomic programming, Omega filed for Chapter 11 in February 2025 and completed its Section 363 asset sale in April 2025 for $14 million to Senda Biosciences (a Flagship Pioneering portfolio company), exceeding the original $9.92 million stalking-horse bid from Pioneering Medicines 08-B.
The company was delisted from Nasdaq in February 2025 and now operates as OMGA Liquidating, Inc. Debtor counsel was Morris Nichols Arsht & Tunnell LLP; creditors' committee counsel was Cole Schotz PC.Omega's platform aimed to modulate gene expression through epigenomic controllers—engineered transcription factors designed to bind specific genomic loci and recruit chromatin-modifying enzymes (such as histone deacetylases, methyltransferases, or demethylases) to silence or activate target genes by altering the epigenetic landscape rather than permanently editing the DNA sequence.
The approach targeted insulated genomic domains (IGDs), discrete regulatory units within the three-dimensional genome architecture where enhancers, promoters, and insulators colocalize within topologically associating domains to coordinately regulate gene expression.By programming epigenomic modifications at IGD boundaries, Omega sought to achieve durable but reversible gene modulation—a middle ground between transient RNA interference and permanent CRISPR editing.
Despite the scientific elegance, the company was unable to generate sufficient clinical momentum to sustain operations, underscoring the persistent "valley of death" between platform innovation and clinical proof of concept in epigenetic medicine.
Regional Market Analysis: South Korea
The week of March 9 marked a significant acceleration in South Korea's positioning as a top-tier destination for global pharmaceutical investment.
Eli Lilly $500 Million MOU
On March 9, 2026, Eli Lilly signed a memorandum of understanding with South Korea's Ministry of Health and Welfare, committing $500 million over five years to the country's pharmaceutical and biotech ecosystem. The investment encompasses the establishment of a Lilly Gateway Labs incubator—built in collaboration with Samsung Biologics at its Bio Campus II in Songdo, Incheon—a five-story, 11,600+ square meter facility with capacity for up to 30 biotech companies (jointly selected by Lilly and Samsung Biologics), with completion expected by July 2027.
The Gateway Labs will be Lilly's first in Asia outside China (where the Beijing site opened in 2025) and seventh globally. The MOU also covers clinical trial infrastructure expansion, R&D collaboration with domestic companies, and biotech startup support.
The announcement followed Roche's similar $484 million (710 billion won) five-year commitment signed on March 3, 2026, aimed at building a global clinical trial ecosystem in South Korea.
Industry analysts noted that the back-to-back investments from two top-five global pharma companies signal South Korea's emergence as a preferred Asian innovation base, driven by its third-ranked global clinical pipeline, established CDMO capacity through Samsung Biologics and Celltrion, and government initiatives to accelerate regulatory review timelines.
Eli Lilly $3 Billion China Manufacturing Commitment
In a separate and concurrent strategic move, Eli Lilly announced on March 11, 2026, a $3 billion investment over ten years to expand localized oral dosage manufacturing capacity in China, primarily to support production of orforglipron—its oral, non-peptide GLP-1 receptor agonist currently under review by China's National Medical Products Administration (NMPA).
Orforglipron represents a fundamental advance over injectable semaglutide and tirzepatide: it is a small-molecule agonist rather than a peptide, meaning it can be manufactured using conventional small-molecule chemistry (tableting, coating, encapsulation) rather than the complex peptide synthesis and fill-finish processes that have constrained GLP-1 supply globally.
As a non-peptide, orforglipron is not degraded by gastrointestinal proteases and does not require the absorption-enhancing permeation technology (such as the SNAC capsule used by oral semaglutide/Rybelsus), enabling standard oral tablet formulation with potentially superior bioavailability and manufacturing scalability.
In Phase 3 trials, orforglipron demonstrated weight reductions of up to 14.7% in obesity and significant HbA1c improvements in type 2 diabetes, positioning it as a potential first oral non-peptide GLP-1 therapy to reach market.
The commitment includes expansion of Lilly's existing Suzhou manufacturing plant, development of external CDMO partnerships—anchored by a specific $200 million deal with Pharmaron Beijing for oral solid dosage capacity—and investment in supply chain localization.
The China investment brings Lilly's total committed capital in the Asia-Pacific region to approximately $6 billion, underscoring the company's strategy to build manufacturing proximity to key markets for its GLP-1 franchise.
Corporate Innovation and Strategic Moves
On March 12, 2026, Pfizer announced the shutdown of Pfizer Ignite, its biotech incubation program designed to accelerate promising therapies from select companies. Ignite's FY2025 revenue was approximately $41 million, down 50% from $82 million the prior year. Unit head Kathy Fernando departed for Replicate Bioscience.
Known portfolio companies included Acepodia (collaboration mutually terminated May 2025), Cardiff Oncology, Mabylon, and CellCentric; under the Ignite model, biotech partners retained ongoing decision-making autonomy for their programs, so the shutdown means loss of Pfizer R&D services and manufacturing capabilities but retention of all IP and programs by the portfolio companies.
The closure stands in contrast to Eli Lilly's simultaneous expansion of its Gateway Labs incubator network—a global chain of co-located lab and office facilities designed to house early-stage biotech companies and accelerate their access to Lilly's R&D, manufacturing, and clinical infrastructure—into South Korea and its $1 billion Nvidia co-innovation lab (announced at JPM26 in January), suggesting that the industry is bifurcating between companies that view external innovation as a core operating function and those retrenching toward traditional internal R&D models.
Tilray Medical / CC Pharma / Alliance Healthcare Deutschland Distribution Alliance
On March 12, 2026, Tilray Medical, CC Pharma, and 14U Pharma announced a strategic alliance with Alliance Healthcare Deutschland to strengthen their combined presence in the German pharmacy market.
Effective April 1, 2026, the partnership leverages Alliance Healthcare's network of 27 logistics centers serving over 10,000 pharmacies across Germany, expanding distribution capacity for Tilray's medical cannabis and pharmaceutical products portfolio.
Germany legalized recreational cannabis in April 2024 and has established one of Europe's largest regulated medical cannabis markets, with prescriptions dispensed through the standard pharmacy channel.
The alliance positions Tilray to capture growing demand as both medical and adult-use market infrastructure develops, building on CC Pharma's established position as a licensed pharmaceutical wholesaler and 14U Pharma's cannabis import and distribution capabilities.
CNS Pharmaceuticals Pipeline Divestiture
On March 11, 2026, CNS Pharmaceuticals announced its intention to divest its glioblastoma pipeline candidates berubicin and TPI 287 while pursuing new lead assets in neurology and oncology.
Berubicin is an anthracycline chemotherapeutic (structurally related to doxorubicin) that was specifically designed to cross the blood-brain barrier—a property that distinguishes it from other anthracyclines, which are excluded from the central nervous system by P-glycoprotein efflux pumps.
Berubicin intercalates into DNA and inhibits topoisomerase II, inducing double-strand breaks in rapidly dividing glioblastoma cells. TPI 287 is a synthetic taxane that similarly penetrates the blood-brain barrier and stabilizes microtubules, preventing the mitotic spindle disassembly required for cell division.
Despite their mechanistic rationale, neither compound generated sufficient clinical momentum to sustain continued development as a standalone program. The company disclosed engagement of a consulting firm to support the strategic transition.
Conclusion: Synthesis and Future Outlook
The healthcare and biotech transactions of March 9–13, 2026, reveal a sector that is increasingly bifurcated between high-performing leaders and capital-constrained laggards. The week's activity provides several critical insights into the future of the industry.
First, the "tuck-in" M&A model remains the primary engine of revenue growth. Large-cap biopharma companies are using their $2.1 trillion in firepower not for high-risk mega-mergers, but for the systematic acquisition of de-risked assets (like Biocare or Scientia) that can be immediately funneled through existing global commercial channels.
Second, the public capital markets demonstrated exceptional depth for high-conviction stories. Dianthus ($719M) and Xenon ($747.5M) both launched, priced at upsizes, and closed with full exercise of underwriter options within the same week—a combined $1.47 billion in biotech follow-on equity raised in five trading days, both catalyzed by positive Phase 3 data (claseprubart's early GO in CIDP for Dianthus; azetukalner's X-TOLE2 focal seizure results for Xenon).
The pattern is instructive: both offerings were mechanism-driven—classical complement pathway inhibition and Kv7 potassium channel opening, respectively—representing genuinely novel biology rather than incremental improvements to existing drug classes.
Adding the CRISPR Therapeutics ($550M) and Indivior ($450M) upsized convertible notes, Relmada's $160M oversubscribed PIPE (funding the NMDA receptor antagonist esmethadone program), and Galderma's EUR500M Eurobond, the week's total new capital raised across life sciences—including the MiniMed $560M IPO and the Salspera, BioXcel, and Prelude transactions—exceeded $3.8 billion, representing one of the strongest weeks for biotech capital formation since the 2021 peak.
Separately, the EQT-led consortium's final exit from Galderma Group AG via a CHF 4.9 billion (~$6.3 billion) accelerated bookbuild—the largest sponsor-backed block trade in history, generating a more than fourfold return on the consortium's 2019 Nestlé carve-out—demonstrated that private equity liquidity in healthcare remains robust even amid elevated market volatility, and underscored dermatology's emergence as one of the highest-returning therapeutic verticals for financial sponsors.
Third, the GLP-1 ecosystem continued to evolve dramatically. The Hims & Hers/Novo Nordisk collaboration represents a new distribution paradigm that bridges direct-to-consumer telehealth platforms with branded pharmaceutical supply, potentially reshaping how obesity treatments reach the estimated 100 million American adults living with obesity.
Simultaneously, Eli Lilly's $3 billion China manufacturing commitment—including a $200 million CDMO deal with Pharmaron—signals that the GLP-1 supply chain race has entered a new phase where localized production at scale is becoming a competitive necessity, not merely an option.
The China investment is specifically designed to support orforglipron, Lilly's oral non-peptide GLP-1 agonist, whose small-molecule manufacturing profile could fundamentally alter the supply constraint dynamics that have defined the GLP-1 market since 2023.
Fourth, the divergence in corporate innovation models is sharpening. Pfizer shut down its Ignite incubator—with FY2025 revenue down 50% to $41 million—on the same day Lilly expanded its Gateway Labs into South Korea (an 11,600 sqm facility for 30 companies at Samsung Biologics' Bio Campus II) and committed $3 billion to China. These moves reflect fundamentally different views on the role of external innovation ecosystems and regional manufacturing proximity in sustaining long-term competitive advantage.
Fifth, European deep-tech life sciences continues to develop critical enabling technologies. From VALANX's site-specific ADC conjugation platform in Vienna to CRISPR Therapeutics' $550M convertible notes issued from Zug—funding an expanding gene-editing franchise that spans ex vivo hematopoietic stem cell editing (Casgevy) through in vivo liver-targeted CRISPR for cardiovascular disease—European-headquartered companies are both generating platform innovations and accessing US capital markets at scale.
Sixth, the week's clinical data readouts underscored both the breadth of innovation and the competitive intensity across therapeutic areas. AbbVie's ABBV-295 Phase 1 amylin data (up to 9.8% weight loss at 13 weeks) validated a non-incretin obesity mechanism and signaled that the metabolic space is expanding beyond the GLP-1 duopoly. BridgeBio's FORTIFY data positioned BBP-418 as a potential first-ever approved therapy for any form of limb-girdle muscular dystrophy, with an NDA submission expected in the first half of 2026.
Ultragenyx's DTX301 gene therapy demonstrated meaningful ammonia reduction in OTC deficiency—a result with implications for the broader AAV gene therapy field. And UCB's BE BOLD head-to-head superiority of bimekizumab over risankizumab in psoriatic arthritis intensified the competitive dynamics in the immunology space, directly impacting the positioning of AbbVie/Boehringer Ingelheim's Skyrizi franchise.
As the industry progresses into the second quarter of 2026, the combination of impending patent cliffs and record financial firepower suggests that the robust pace of dealmaking is likely to persist through the remainder of the fiscal year.
The information provided in this report is for informational purposes only. The author is not a lawyer, financial adviser, or investment professional. Nothing in this publication constitutes investment advice, legal advice, or a recommendation to buy or sell any security. Readers should conduct their own due diligence and consult qualified professionals before making any investment or business decisions.
Member discussion